Literature DB >> 31768834

Evolving Strategies to Manage Clostridium difficile Colitis.

Jessica A Bowman1, Garth H Utter2,3.   

Abstract

Clostridium difficile infection remains a common nosocomial illness with a significant impact on health care delivery. As molecular phenotyping of this organism has changed our understanding of its transmission and virulence, so too have diagnostic methods and treatment strategies evolved in recent years. The burden of this infection falls predominantly on elderly patients with comorbidities who have recently received antibiotics. Oral or enteral vancomycin is now preferred for first-line antimicrobial treatment across the disease spectrum, including mild-moderate initial cases. Fidaxomicin (a novel macrolide antibiotic), bezlotoxumab (a monoclonal antibody against toxin TcdB), and fecal microbiota transplantation expand the therapeutic armamentarium, particularly for recurrent infection. Operative treatment should be reserved for patients with fulminant infection, and early identification of patients who would benefit from an operation remains a challenge. Less invasive surgical options-such as laparoscopic diverting ileostomy with colonic irrigation-may improve survival and other outcomes relative to total abdominal colectomy and represent an attractive alternative particularly for frail patients.

Entities:  

Keywords:  Clostridium difficile colitis; Pseudomembranous colitis

Year:  2019        PMID: 31768834      PMCID: PMC7031036          DOI: 10.1007/s11605-019-04478-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  50 in total

1.  Comparison of Outcomes Between Total Abdominal and Partial Colectomy for the Management of Severe, Complicated Clostridium Difficile Infection.

Authors:  David Peprah; Alexander S Chiu; Raymond A Jean; Kevin Y Pei
Journal:  J Am Coll Surg       Date:  2018-12-18       Impact factor: 6.113

2.  Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.

Authors:  Dina Kao; Brandi Roach; Marisela Silva; Paul Beck; Kevin Rioux; Gilaad G Kaplan; Hsiu-Ju Chang; Stephanie Coward; Karen J Goodman; Huiping Xu; Karen Madsen; Andrew Mason; Gane Ka-Shu Wong; Juan Jovel; Jordan Patterson; Thomas Louie
Journal:  JAMA       Date:  2017-11-28       Impact factor: 56.272

3.  Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach.

Authors:  Monika Fischer; Brian Sipe; Yao-Wen Cheng; Emmalee Phelps; Nicholas Rogers; Sashidhar Sagi; Matthew Bohm; Huiping Xu; Zain Kassam
Journal:  Gut Microbes       Date:  2016-12-21

4.  Loop ileostomy versus total colectomy as surgical treatment for Clostridium difficile-associated disease: An Eastern Association for the Surgery of Trauma multicenter trial.

Authors:  Paula Ferrada; Rachael Callcut; Martin D Zielinski; Brandon Bruns; Daniel Dante Yeh; Tanya L Zakrison; Jonathan P Meizoso; Babak Sarani; Richard D Catalano; Peter Kim; Valerie Plant; Amelia Pasley; Linda A Dultz; Asad J Choudhry; Elliott R Haut
Journal:  J Trauma Acute Care Surg       Date:  2017-07       Impact factor: 3.313

5.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

Authors:  Oliver A Cornely; Derrick W Crook; Roberto Esposito; André Poirier; Michael S Somero; Karl Weiss; Pamela Sears; Sherwood Gorbach
Journal:  Lancet Infect Dis       Date:  2012-02-08       Impact factor: 25.071

Review 6.  Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review.

Authors:  D B Stewart; C S Hollenbeak; M Z Wilson
Journal:  Colorectal Dis       Date:  2013-07       Impact factor: 3.788

7.  Overwhelming Recurrent Clostridium difficile Infection after Reversal of Diverting Loop Ileostomy Created for Prior Fulminant C. difficile Colitis.

Authors:  Anna Z Fashandi; Scott R Ellis; Philip W Smith; Peter T Hallowell
Journal:  Am Surg       Date:  2016-08       Impact factor: 0.688

8.  Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

Authors:  Derrick W Crook; A Sarah Walker; Yin Kean; Karl Weiss; Oliver A Cornely; Mark A Miller; Roberto Esposito; Thomas J Louie; Nicole E Stoesser; Bernadette C Young; Brian J Angus; Sherwood L Gorbach; Timothy E A Peto
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

Review 9.  Clostridium difficile infection in the elderly: an update on management.

Authors:  Tomefa E Asempa; David P Nicolau
Journal:  Clin Interv Aging       Date:  2017-10-24       Impact factor: 4.458

10.  Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.

Authors:  Dilip Nathwani; Oliver A Cornely; Anke K Van Engen; Olatunji Odufowora-Sita; Peny Retsa; Isaac A O Odeyemi
Journal:  J Antimicrob Chemother       Date:  2014-08-05       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.